Seeking Alpha
 

Merck & Co Inc. (MRK)

- NYSE
Show Summaries  |  Hide Summaries
  • Apr. 18, 2013, 12:10 AM
    Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT
    | Comment!
  • Apr. 17, 2013, 5:35 PM
    Notable earnings after Thursday’s close: ACTG, ALGN, AMD, BGS, CBST, CE, CMG, COF, CPHD, ETFC, GOOG, IBM, ISRG, LSCC, MSFT, RMBS, VMI, WIT
    | Comment!
  • Apr. 10, 2013, 1:37 PM
    Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 
    | 6 Comments
  • Apr. 10, 2013, 12:28 PM
    Jim Cramer likes what he sees in Merck (MRK +2.1%) right now, saying the stock is lagging its peers, trading at just about 12x earnings versus a richer 14x the rest of the sector. Patent cliff fears for this stock are pretty well mitigated, Cramer says. The company has no fewer than five solid drugs in development, and while none may be a home run, the pipeline should bolster growth over the next few years. He thinks the stock should be trading somewhere closer $60 right now.
    | 1 Comment
  • Apr. 10, 2013, 8:48 AM
    The FDA accepts Merck's (MRK) NDA application for a tablet version of the company's Noxafil antifungal medicine, which it already markets in an oral liquid form. (PR)
    | Comment!
  • Apr. 4, 2013, 4:45 AM
    The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
    | 5 Comments
  • Apr. 3, 2013, 11:31 AM
    Cubist Pharmaceuticals (CBST -3.1%) falls after Cantor Fitzgerald says the company's development of a competing product indicates it likely isn't preparing to bid for Optimer Pharmaceuticals (OPTR +0.1%). Analyst Irina Rivkind downgraded the stock to Sell Wednesday. (See: Optimer surges on takeover chatter)
    | Comment!
  • Apr. 2, 2013, 7:05 PM
    Citi strategists tweak the criteria for their top dividend-paying stock picks, lowering the standard for dividend yield while adding a new filter for dividend momentum “to give more emphasis on dividend safety and growth." The full list: MO, AEP, T, AVB, BMY, ED, D, DD, DUK, INTC, KMB, KRFT, LLY, MCD, MRK, MSFT, NU, NOC, OXY, PFE, PM, RTN, SRE, SO, SYY, XEL.
    | 5 Comments
  • Apr. 2, 2013, 10:02 AM
    Optimer Pharmaceuticals (OPTR) surges 18.1% following a report that the antibiotics maker has attracted takeover interest from GlaxoSmithKline (GSK), AstraZeneca (AZN), Cubist Pharmaceuticals (CBST) and Japan's Astellas. Optimer hopes to fetch up to $1B in an auction, well above its market cap of $660M. The company has one drug on the market, Dificid, which is used to treat intestinal infections in hospitalized patients.
    | 1 Comment
  • Mar. 27, 2013, 10:30 AM
    Merck (MRK -0.7%) says that the Biologics License Application for its investigational Timothy grass pollen allergy tablet has been accepted for review by the FDA. The tablet provides an alternative to shots for one of the most common seasonal allergic maladies, and is supported by extensive data from Phase III testing, which included a long-term, multi-season trial. Earlier this month, the company also submitted a similar application for its investigational ragweed pollen AIT.
    | Comment!
  • Mar. 25, 2013, 9:10 AM
    Premarket gainers: ZAZA +21%. ARWR +14%. APOL +9%. TSRX +5%Losers: IDIX -10%. OTT -10%. UTHR -7%. PGTI -6%
    | Comment!
  • Mar. 25, 2013, 5:29 AM
    The Supreme Court is due to hear a "pay for delay" a case today over whether it's legal for drug companies to pay generic rivals tens of millions of dollars to hold off from launching copycat versions of medicines. The case is the FTC vs Actavis (ACT) and involves Abbott Labs' (ABT) AndroGel testosterone treatment. The FTC says the practice costs customers $3.5B a year, while drug firms argue that it protects innovation.
    | 13 Comments
  • Mar. 15, 2013, 3:08 PM
    Oncothyreon (ONTY +0.9%) moves up today on a better than expected Q4 report yesterday, largely shrugging off Cantor Fitzgerald's slashing of its price target to $4.00 from $11.00. The cut relates to ONTY's loss of Stimuvax. Cantor says that despite partner Merck's (MRK) assertion that treatment effects were observed in sub-populations, its financial model assumes that commercialization does not occur and no value is included in its valuation.
    | Comment!
  • Mar. 15, 2013, 1:56 PM
    Cubist Pharmaceuticals (CBST -1.3%) slips on a less-than-stellar initiation at Credit Suisse with a Neutral rating and a $52 price target. The firm says it expects that positive CXA-201 data in the second half will strengthen confidence in the long-term sustainability of it's antibiotic franchise and be the impetus for global expansion.
    | Comment!
  • Mar. 14, 2013, 5:48 PM
    The FDA is reviewing data on a certain class of diabetes drugs which it says might lead to precancerous changes in the pancreas. The drugs may include Eli Lilly's (LLY) Tradjenta, Merck's (MRK) Januvia, Novo Nordisk's (NVO) Victoza, and Bristol-Myers Squibb's (BMY) Byetta. Labels on the drugs already warn of increased potential for pancreatitis, which is the inflamation of the pancreas. The precancerous changes are new, and would affect future labeling.
    | 4 Comments
  • Mar. 13, 2013, 11:52 AM
    Trius Therapeutics (TSRX +3.7%) moves up after reporting a Q4 loss that beat estimates. Revenue was also better, coming in at $5.2M, versus $5M the prior year. Net losses were higher, largely due to clinical and nonclinical development activities for tedizolid phosphate, our lead investigational drug in Phase 3 clinical development.
    | 1 Comment
Visit Seeking Alpha's
MRK vs. ETF Alternatives
Company Description
Merck & Co Inc is a health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products.